Tazobactam

Synonym(s): YTR 830

Class: Beta-lactamase inhibitor (penicillanic acid sulfone)

Details of activity:	Binds irreversibly to beta-lactamases, mainly class A enzymes. No intrinsic antibacterial activity
Combined with other compounds:	Yes
Description:	Semisynthetic, derived from sulbactam. Only available as a combination product, multiple fixed combinations, parenteral application
Institute where first reported:	Wyeth Pharmaceuticals
Year first mentioned:	1982
Highest developmental phase:	Approved by FDA in 1993
Development status:	Approved, off-patent

Chemical structure(s):
Canonical SMILES:	C[C@]1(CN2C=CN=N2)[C@H](C(=O)O)N3C(=O)C[C@H]3S1(=O)=O
Isomeric SMILES:	C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3
InChI:	InChI=1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10+/m1/s1
InChI Key:	LPQZKKCYTLCDGQ-WEDXCCLWSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/123630

External links:
Guide to Pharmacology:	tazobactam
Main Source:	https://journals.asm.org/doi/epdf/10.1128/AAC.29.6.980
Citations:	https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01279 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC179968/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2806661/